메뉴 건너뛰기




Volumn 28, Issue 1, 2006, Pages 26-35

Statin-related adverse events: A meta-analysis

Author keywords

Adverse events; Atorvastatin; Fluvastatin; GP IIb IIIa inhibitors; Lovastatin; Meta analysis; Pravastatin; Rosuvastatin; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

EID: 32844467424     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.005     Document Type: Article
Times cited : (244)

References (25)
  • 1
    • 0035897696 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 2
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines
    • Grundy S.M., Cleeman J.I., Merz C.N. National Heart, Lung, and Blood Institute, and American College of Cardiology Foundation, and the American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines Circulation 110 2004 227 239
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 3
    • 0037414218 scopus 로고    scopus 로고
    • Statin-associated myopathy
    • Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy JAMA 289 2003 1681 1690
    • (2003) JAMA , vol.289 , pp. 1681-1690
    • Thompson, P.D.1    Clarkson, P.2    Karas, R.H.3
  • 4
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
    • Schwartz G.G., Olsson A.G., and Ezekowitz M.D. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial JAMA 285 2001 1711 1718
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 5
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):Multicentre randomised placebo-controlled trial
    • Colhoun H.M., Betteridge D.J., and Durrington P.N. CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):Multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durringtoncards Investigators, P.N.3
  • 6
    • 0036467895 scopus 로고    scopus 로고
    • Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
    • Davidson M., Ma P., and Stein E.A. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia Am J Cardiol 89 2002 268 275
    • (2002) Am J Cardiol , vol.89 , pp. 268-275
    • Davidson, M.1    Ma, P.2    Stein, E.A.3
  • 7
    • 0037504445 scopus 로고    scopus 로고
    • Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blindtrial
    • Ezetimibe Study Group
    • Ballantyne C.M., Houri J., Notarbartolo A. Ezetimibe Study Group Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blindtrial Circulation 107 2003 2409 2415
    • (2003) Circulation , vol.107 , pp. 2409-2415
    • Ballantyne, C.M.1    Houri, J.2    Notarbartolo, A.3
  • 8
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa J.C., Grundy S.M., and Waters D.D. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • Larosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 9
    • 0032904753 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results ofthe fluvastatin angiographic restenosis (FLARE) trial
    • Serruys P.W., Foley D.P., and Jackson G. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results ofthe fluvastatin angiographic restenosis (FLARE) trial Eur Heart J 20 1999 58 69
    • (1999) Eur Heart J , vol.20 , pp. 58-69
    • Serruys, P.W.1    Foley, D.P.2    Jackson, G.3
  • 10
    • 0037178569 scopus 로고    scopus 로고
    • Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
    • Serruys P.W., de Feyter P., and Macaya C. Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial JAMA 287 2002 3215 3222
    • (2002) JAMA , vol.287 , pp. 3215-3222
    • Serruys, P.W.1    De Feyter, P.2    MacAya, C.3
  • 11
    • 0033016149 scopus 로고    scopus 로고
    • The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
    • Riegger G., Abletshauser C., and Ludwig M. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment Atherosclerosis 144 1999 263 270
    • (1999) Atherosclerosis , vol.144 , pp. 263-270
    • Riegger, G.1    Abletshauser, C.2    Ludwig, M.3
  • 12
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
    • Sacks F.M., Pfeffer M.A., and Moye L.A. Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
    • (1996) N Engl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 13
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels N Engl J Med 339 1998 1349 1357
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 14
    • 0029050796 scopus 로고
    • Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels
    • Jukema J.W., Bruschke A.V., and van Boven A.J. Regression Growth Evaluation Statin Study (REGRESS) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels Circulation 91 1995 2528 2540
    • (1995) Circulation , vol.91 , pp. 2528-2540
    • Jukema, J.W.1    Bruschke, A.V.2    Van Boven, A.J.3
  • 15
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
    • West of Scotland Coronary Prevention Study Group
    • Shepherd J., Cobbe S.M., Ford I. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1308
    • (1995) N Engl J Med , vol.333 , pp. 1301-1308
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 16
    • 0028849703 scopus 로고
    • Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC Iinvestigation
    • Pitt B., Mancini G.B., and Ellis S.G. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC Iinvestigation J Am Coll Cardiol 26 1995 1133 1139
    • (1995) J Am Coll Cardiol , vol.26 , pp. 1133-1139
    • Pitt, B.1    Mancini, G.B.2    Ellis, S.G.3
  • 17
    • 4544243333 scopus 로고    scopus 로고
    • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the a to Z trial
    • de Lemos J.A., Blazing M.A., and Wiviott S.D. A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial JAMA 292 2004 1307 1316
    • (2004) JAMA , vol.292 , pp. 1307-1316
    • De Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3
  • 18
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
    • (2002) Lancet , vol.360 , pp. 7-22
  • 19
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Scandinavian Simvastatin Survival Study Group
    • Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 20
    • 0035451307 scopus 로고    scopus 로고
    • Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
    • Olsson A.G., Pears J., and McKellar J. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia Am J Cardiol 88 2001 504 508
    • (2001) Am J Cardiol , vol.88 , pp. 504-508
    • Olsson, A.G.1    Pears, J.2    McKellar, J.3
  • 21
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
    • Downs J.R., Clearfield M., and Weis S. Air Force/Texas Coronary Atherosclerosis Prevention Study Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 22
    • 0037164314 scopus 로고    scopus 로고
    • Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial
    • Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group
    • Shepherd J., Blauw G.J., Murphy M.B. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial Lancet 360 2002 1623 1630
    • (2002) Lancet , vol.360 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 23
    • 2342661718 scopus 로고    scopus 로고
    • What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
    • Sweeting M.J., Sutton A.J., and Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data Stat Med 23 2004 1351 1375
    • (2004) Stat Med , vol.23 , pp. 1351-1375
    • Sweeting, M.J.1    Sutton, A.J.2    Lambert, P.C.3
  • 24
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lip Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • Sever P.S., Dahlof B., and Poulter N.R. ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lip Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet 361 2003 1149 1158
    • (2003) Lancet , vol.361 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulterascot Investigators, N.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.